Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer

Molecular alterations contributing to pancreatic cancer chemoresistance

(2017) Azam Rajabpour et al.   PANCREATOLOGY

Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters

(2017) Patricia Dauer et al.   PANCREATOLOGY

A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer

(2017) Dana B. Cardin et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer

(2016) Tarik Ghadban et al.   APOPTOSIS

Ganetespib radiosensitization for liver cancer therapy

(2016) Sivarajan T. Chettiar et al.   CANCER BIOLOGY & THERAPY

Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation

(2016) Y. Wang et al.   CLINICAL CANCER RESEARCH

Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib

(2016) Ganji Purnachandra Nagaraju et al.   EUROPEAN JOURNAL OF CANCER

High Nuclear Hypoxia-Inducible Factor 1 Alpha Expression Is a Predictor of Distant Recurrence in Patients With Resected Pancreatic Adenocarcinoma

(2015) Lauren E. Colbert et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors

(2015) SHINSUKE HASHIDA et al.   ONCOLOGY REPORTS

The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells

(2015) Diana Spiegelberg et al.   Oncotarget

HIF-1 is a critical target of pancreatic cancer

(2015) Jihui Hao   OncoImmunology

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells

(2015) Roberto Gomez-Casal et al.   Cancers

HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy

(2015) Ganji Purnachandra Nagaraju et al.   Oncotarget

Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation

(2014) Kirtesh Patel et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise

(2014) D. A. Proia et al.   CANCER RESEARCH

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

High expression of heat shock protein 90 alpha and its significance in human acute leukemia cells

(2014) Wen-Liang Tian et al.   GENE

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

(2014) Suqin He et al.   INVESTIGATIONAL NEW DRUGS

Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: A meta-analysis

(2014) Long-Yun Ye et al.   PANCREATOLOGY

HIF-1 Alpha Overexpression Correlates with Poor Overall Survival and Disease-Free Survival in Gastric Cancer Patients Post-Gastrectomy

(2014) Li Chen et al.   PLoS One

Erratum to: Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3

(2013) Ganji Purnachandra Nagaraju et al.   ANGIOGENESIS

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

(2013) Jonathan W Goldman et al.   BMC CANCER

3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing

(2013) Paola Longati et al.   BMC CANCER

Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells

(2013) S Carbajo-Pescador et al.   BRITISH JOURNAL OF CANCER

Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer

(2013) Lisha Xiang et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

High Expression of Heat Shock Protein 90 Is Associated with Tumor Aggressiveness and Poor Prognosis in Patients with Advanced Gastric Cancer

(2013) Jiahong Wang et al.   PLoS One

Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990

(2013) Dušan Milanović et al.   Radiation Oncology

Hsp90 — a potential prognostic marker in CML

(2012) Markéta Žáčková et al.   BLOOD CELLS MOLECULES AND DISEASES

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

(2011) György Bodoky et al.   INVESTIGATIONAL NEW DRUGS

Hsp90 Inhibitor-Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage

(2011) K. Ha et al.   MOLECULAR CANCER THERAPEUTICS

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

(2011) W. Ying et al.   MOLECULAR CANCER THERAPEUTICS

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction

(2010) L Stingl et al.   BRITISH JOURNAL OF CANCER

Targeting Heat Shock Protein 90 Overrides the Resistance of Lung Cancer Cells by Blocking Radiation-Induced Stabilization of Hypoxia-Inducible Factor-1α

(2009) Woo-Young Kim et al.   CANCER RESEARCH